Payload Information
General Information of This Payload
| Payload ID | PAY0CGMMP |
|||||
|---|---|---|---|---|---|---|
| Name | Trojan TLR7/8a |
|||||
| Synonyms |
Trojan TLR7/8a
Click to Show/Hide
|
|||||
| Target | Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8) | |||||
| Formula | C17H22N4O2 |
|||||
| Isosmiles | CCOCC(N1CC(C)(O)C)=NC(C(N)=N2)=C1C3=C2C=CC=C3 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
|
|||||
| InChIKey |
BXNMTOQRYBFHNZ-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
314.389 |
Polar area |
86.19 |
||
Complexity |
824.472551 |
xlogp Value |
2.4741 |
|||
Heavy Count |
23 |
Rot Bonds |
5 |
|||
Hbond acc |
6 |
Hbond Donor |
2 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | -0.07 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.07 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.25 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.25 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -47.17 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 0.0666 | ug.mL-1 |
HEK293 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 0.15 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 0.3629 | ug.mL-1 |
HEK293 cells
|
Normal
|
||
| Cellular activity | <0.5 | IU/ml |
Splenocyte cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 11 | IU/ml |
Splenocyte cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 1176 | IU/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 120 | pg/ml |
PBMC cells
|
Normal
|
||
| Cellular activity | 12500 | pg/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 13 | IU/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 1408 | pg/ml |
PBMC cells
|
Normal
|
||
| Cellular activity | 1491 | pg/ml |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 16 | pg/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 1714 | IU/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 1738 | pg/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 19.75 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 190 | pg/ml |
PBMC cells
|
Normal
|
||
| Cellular activity | 19750 | pg/ml |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 2 | ug ml-1 |
PBMC cells
|
Normal
|
||
| Cellular activity | 2.8 | IU/ml |
Splenocyte cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 21 | pg/ml |
PBMC cells
|
Normal
|
||
| Cellular activity | 2134 | pg/ml |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 236 | pg/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 26 | pg/ml |
PBMC cells
|
Normal
|
||
| Cellular activity | 2800 | pg/ml |
PBMC cells
|
Normal
|
||
| Cellular activity | 29.8 | % |
Peritoneal macrophage cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 38 | pg/ml |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 380 | pg/ml |
PBMC cells
|
Normal
|
||
| Cellular activity | 4 | IU/ml |
Splenocyte cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 44037 | IU/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 49 | pg/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 49.9 | % |
B16-F10 cells
|
Mouse melanoma
|
||
| Cellular activity | 600 | pg/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 65.8 | % |
Peritoneal macrophage cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 7 | IU/ml |
Splenocyte cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 7 | IU/ml | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 7.4 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 72 | pg/ml |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 8.27 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 8.7 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 1.25 | nM |
PBMC cells
|
Normal
|
||
| Cellular activity | <1.25 | nM |
PBMC cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 1259 | nM |
PBMC cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 1340 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 1400 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 1500 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 1500 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 1500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 1500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 1500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Maximum Effect (Emax) | 1870 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Cytotoxic Concentration (CC50) | >20000 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2056 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 24 | nM |
PBMC cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 250 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 26.5 | nM |
PBMC cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 260.1 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 3000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 310 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 330 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 3500 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 4000 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 420 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 420 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 420 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 420 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 4500 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 4500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 4500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 4500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 480 | nM |
HEK293 cells
|
Normal
|
||
| Cellular activity | 5.61 | nM |
PBMC cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 5870 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 6130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 616 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 6400 | nM |
HEK293 cells
|
Normal
|
||
| Cellular activity | 7.26 | nM |
PBMC cells
|
Normal
|
||
| Cellular activity | 7.75 | nM |
PBMC cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 75 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 750 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 760 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 9600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.1 | uM |
PBMC cells
|
Normal
|
||
| Cellular activity | 1 | uM |
PBMC cells
|
Normal
|
||
| Cellular activity | 1 | uM |
PBMC cells
|
Normal
|
||
| Cellular activity | 1 | uM |
PBMC cells
|
Normal
|
||
| Maximum Effect (Emax) | 10 | uM |
PBMC cells
|
Normal
|
Each Antibody-drug Conjugate Related to This Payload